Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.
Large screening reveals NTRK fusions in lung cancer are rarer than expected, refining which patients should receive targeted drugs.
The ETOP Lungscape consortium screened 25,946 NSCLC patients for NTRK fusions, providing the most definitive prevalence estimate for this actionable biomarker in lung cancer. Clinicopathologic features associated with NTRK-positive NSCLC were characterized, directly supporting refined patient selection criteria for larotrectinib and entrectinib in routine NSCLC practice.
What the study was
- Study design
- Large-scale multicenter prevalence study
- Population
- 25,946 NSCLC patients from ETOP Lungscape consortium
- Sample size
- 25946
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Lung cancer (Amsterdam, Netherlands)
Why it surfaced
Lung Cancer journal; largest NTRK prevalence study in NSCLC (n=25,946); ETOP Lungscape multicenter consortium; directly actionable for TRK inhibitor screening programs.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.